{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:20:12Z","timestamp":1762917612548},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.contraception.2015.10.007","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T18:23:14Z","timestamp":1445710994000},"page":"249-256","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of a 21\/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol"],"prefix":"10.1016","volume":"93","author":[{"given":"Robin","family":"Kroll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ricciotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.contraception.2015.10.007_bb0005","first-page":"CD004861","article-title":"Types of progestogens in combined oral contraception: effectiveness and side-effects","author":"Lawrie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2015.10.007_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2013.844229","article-title":"Pharmacokinetic evaluation of desogestrel as a female contraceptive","volume":"10","author":"Grandi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/13625180400007736","article-title":"Clinical profile of contraceptive progestins","volume":"9","author":"Benagiano","year":"2004","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2015.10.007_bb0020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/0002-9378(93)90333-E","article-title":"Combined oral contraception with desogestrel\/ethinyl estradiol: tolerability profile","volume":"168","author":"Kaunitz","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","article-title":"Desogestrel, norgestimate, and gestodene: the newer progestins","volume":"29","author":"Kaplan","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.contraception.2015.10.007_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.contraception.2007.09.010","article-title":"Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive","volume":"77","author":"Reape","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0035","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0029-7844(96)00488-7","article-title":"Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms","volume":"89","author":"Sulak","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0045","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0002-9378(98)70292-3","article-title":"Ovarian activity in women taking an oral contraceptive containing 20\u03bcg ethinyl estradiol and 150\u03bcg desogestrel: effects of low estrogen doses during the hormone-free interval","volume":"179","author":"Killick","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00404-012-2545-6","article-title":"Evaluation of hormonal suppression with two contraceptive regimens using ethinyl estradiol and desogestrel","volume":"287","author":"Gassen","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.contraception.2015.10.007_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2008.04.001","article-title":"Efficacy and safety of a 28-day oral contraceptive with 7days of low-dose estrogen in place of placebo","volume":"78","author":"Poindexter","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0060","author":"European Medicines Agency"},{"key":"10.1016\/j.contraception.2015.10.007_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.contraception.2009.07.003","article-title":"The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol","volume":"81","author":"Kroll","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0010-7824(03)00141-0","article-title":"A multicenter, randomized study of an extended cycle oral contraceptive","volume":"68","author":"Anderson","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0075","series-title":"Lybrel (90mcg levonorgestrel and 20mcg ethinyl estradiol) tablets [prescribing information]","author":"Wyeth Pharmaceuticals Inc","year":"2010"},{"key":"10.1016\/j.contraception.2015.10.007_bb0080","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0085","series-title":"Final summary minutes: Advisory Committee for Reproductive Health Drugs meeting","author":"U.S. Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.contraception.2015.10.007_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.contraception.2011.01.002","article-title":"Effect of extended-cycle regimen with an oral contraceptive containing 30mcg ethinylestradiol and 2mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy","volume":"84","author":"Wiegratz","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/humupd\/8.4.345","article-title":"Residual ovarian activity during oral steroid contraception","volume":"8","author":"van Heusden","year":"2002","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2015.10.007_bb0100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.contraception.2004.05.006","article-title":"Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use","volume":"70","author":"Baerwald","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ajog.2004.02.012","article-title":"Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression","volume":"190","author":"Schlaff","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0110","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0002-9378(99)70362-5","article-title":"Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100\u03bcg levonorgestrel and 20\u03bcg ethinyl estradiol (Alesse\u00ae)","volume":"181","author":"Archer","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20\u03bcg ethinylestradiol and 3mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0120","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/AOG.0b013e318250c3a0","article-title":"Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17\u03b2-estradiol: a randomized controlled trial","volume":"119","author":"Westhoff","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.contraception.2015.10.007_bb0130","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.10.007_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/13625187.2011.643836","article-title":"Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis","volume":"17","author":"Martinez","year":"2012","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2015.10.007_bb0140","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.10.007_bb0145","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.10.007_bb0150","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2015.10.007_bb0155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.contraception.2006.02.002","article-title":"Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel","volume":"73","author":"Jick","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0160","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.10.007_bb0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jfprhc-2011-100260","article-title":"Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets","volume":"38","author":"Dinger","year":"2012","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2015.10.007_bb0170","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1097\/AOG.0b013e318277c93b","article-title":"ACOG Committee Opinion Number 540: risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills","volume":"120","author":"ACOG Committee on Practice Bulletins \u2014 Gynecology","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/AOG.0b013e31825194ca","article-title":"Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective","volume":"119","author":"Raymond","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.contraception.2012.06.010","article-title":"Communicating risk: does scientific debate compromise safety?","volume":"86","author":"Jensen","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0185","author":"European Medicines Agency"},{"key":"10.1016\/j.contraception.2015.10.007_bb0190","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2015.10.007_bb0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/AOG.0b013e3182994c43","article-title":"Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis","volume":"122","author":"Peragallo Urrutia","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0200","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0002-9378(98)70290-X","article-title":"An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive","volume":"179","author":"The Mircette Study Group","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2015.10.007_bb0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.contraception.2005.09.010","article-title":"Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol","volume":"73","author":"Anderson","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.contraception.2014.01.013","article-title":"Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel\/ethinyl estradiol combined oral contraceptive","volume":"89","author":"Portman","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2015.10.007_bb0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.contraception.2011.12.009","article-title":"Bleeding profile of a flexible extended regimen of ethinylestradiol\/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study","volume":"86","author":"Jensen","year":"2012","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078241500623X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078241500623X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T08:29:18Z","timestamp":1617438558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078241500623X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S001078241500623X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2015.10.007","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of a 21\/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2015.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}